Drugs Xagena
The FDA released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex ( celecoxib ): The Food and Drug Administration (FDA) learned from the National Cancer In ...
After evaluation of the available data, and consideration of submissions from patients and health professionals, the Medicines Adverse Reactions Committee ( MARC ) has recommended that the COX-2 inhib ...
Researchers from University of Pennsylvania School of Medicine have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and ...
The FDA ( Food and Drug Administration ) has approved the selective COX-2 inhibitor Celebrex ( Celecoxib ) for the relief of the signs and symptoms associated with ankylosing spondylitis, a form of a ...
Cox-2 selective inhibitors are used to relieve pain resulting from a variety of musculoskeletal disorders. Numerous studies have shown that their effectiveness in pain relief is similar to "tradition ...
An identified path of inflammation once thought to be wholly independent of other inflammatory systems has now been linked to another major pathway. The findings by neuroscientists at Johns Hopkins a ...
Researchers at the National Yang-Ming University, Taipei, ( Taiwan ) assessed the risk of acute myocardial infarction, angina, stroke and transient ischaemic attack ( TIA ) in long-term users of Rofec ...
A study by investigators at the McGill University Health Centre ( MUHC ) found that a quarter of patients who suffered a myocardial infarction while taking Vioxx ( Rofecoxib ) did so within the firs ...
Researchers at the University of California School of Medicine, San Francisco, have examined the association between long-term use of nonsteroidal antiinflammatory drugs ( NSAIDs ) and non-Hodgkin lym ...
The FDA ( Food and Drug Administration ) has approved Celebrex ( Celecoxib ) for a new use: the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients two years of age and older ...
Myocardial infarction survivors taking COX-2-selective (NSAIDs) inhibitors or high dosages of nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) are at a greater risk of a second myocardial i ...
Researchers at University of Manchester, UK, evaluated the risk of myocardial infarction associated with the use of selective cyclooxygenase-2 ( COX-2 ) inhibitors ( coxibs ). A systematic review ...
A study has shown that Celecoxib ( Celebrex ) and other anti-inflammatory coxib medications may counter the positive effects of Acetylsalicylic acid ( Aspirin ) in preventing blood clots. The resea ...
The FDA ( Food and Drug Administration ) has approved the first generic versions of Celebrex ( Celecoxib ) capsules, a treatment for rheumatoid arthritis, osteoarthritis, short-term ( acute ) pain, an ...
